Efficacy and Tolerability of a Novel Cosmetic and Over‐the‐Counter Facial Acne Regimen Versus a Prescription Treatment
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.16568 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Priscilla Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Allergan Aesthetics, an AbbVie Company, Irvine, California, USA. Hauptthemen laut MEDLINE: Acne Vulgaris, Dermatologic Agents, Nonprescription Drugs. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergan Aesthetics, an AbbVie Company, Allergan Aesthetics.
Abstract (Originalsprache)
Background
The SkinMedica Acne Treatment Platform (SM Regimen) was formulated to treat acne without overdrying the skin. We evaluated efficacy and tolerability of the SM Regimen (including a novel 1% salicylic acid Acne Clarifying Cleanser and 2% salicylic acid Acne Treatment Lotion) versus a prescription formulation (Rx Regimen; including adapalene 0.1%/benzoyl peroxide 2.5%) in a diverse population of adults with mild to moderate facial acne.
Methods
This single‐center, double‐blind, randomized study enrolled adults (18–45 years) with Fitzpatrick skin types (FST) I–VI. SM Regimen or Rx Regimen was applied topically to the entire face for 12 weeks. Assessments were conducted at 24 and 48 h and 4, 8, and 12 weeks.
Results
Subjects (SM Regimen, n = 31; Rx Regimen, n = 23) were primarily female (90.7%) with mean age of 28.6 years; 53.8% had FST IV–VI. Efficacy was comparable between regimens. The SM regimen resulted in significant improvements versus baseline in mean Investigator's Global Assessment of acne severity from 48 h through week 12 ( p ≤ 0.001), as well as significant and sustained improvements from baseline in total acne lesion count, global postinflammatory hyperpigmentation/postinflammatory erythema, and oiliness. The SM Regimen was well tolerated at all time points, with mean scores below mild for all parameters; the Rx Regimen caused significantly more tightness/dry feeling at week 4 versus SM Regimen ( p = 0.008). Subjects (> 96%) reported high satisfaction with the SM Regimen at all time points.
Conclusions
The SM Regimen reduced acne severity and skin oiliness, evening out skin tone without overdrying or irritating the skin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.
- SGS Stephens Inc., Richardson, Texas, USA.
ORCID-Profile: Priscilla Huang, Olivia Supan, Cecilia L Pak, Rahul C Mehta, Elizabeth T Makino
Förderung
- Allergan Aesthetics, an AbbVie Company
- Allergan Aesthetics
Zitieren
APA
Huang, P., Supan, O., Pak, C. L., Mehta, R. C., & Makino, E. T. (2025). Efficacy and Tolerability of a Novel Cosmetic and Over‐the‐Counter Facial Acne Regimen Versus a Prescription Treatment. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16568
Vancouver
Huang P, Supan O, Pak CL, Mehta RC, Makino ET. Efficacy and Tolerability of a Novel Cosmetic and Over‐the‐Counter Facial Acne Regimen Versus a Prescription Treatment. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16568
BibTeX
@article{Huang2025,
author = {Huang, Priscilla and Supan, Olivia and Pak, Cecilia L and Mehta, Rahul C and Makino, Elizabeth T},
title = {Efficacy and Tolerability of a Novel Cosmetic and Over‐the‐Counter Facial Acne Regimen Versus a Prescription Treatment},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.16568}
}
EUVIMED